{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=39", "query": { "condition": "B-Cell Non-Hodgkin Lymphoma", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 2217, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T01:25:27.974Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01682044", "title": "Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Small Lymphocytic Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "western blotting", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE", "GENETIC" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 20, "start_date": "2007-04-17", "completion_date": "2016-12-22", "has_results": true, "last_update_posted_date": "2017-10-09", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682044" }, { "nct_id": "NCT00093314", "title": "HuMax-CD20 in Chronic Lymphocytic Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "HuMax-CD20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2004-10", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2015-04-21", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093314" }, { "nct_id": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ALLO-501A", "type": "GENETIC" }, { "name": "ALLO-647", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL", "DRUG" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2020-05-21", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 24, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416984" }, { "nct_id": "NCT00134004", "title": "Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "74 Years", "sex": "ALL", "summary": "6 Months to 74 Years" }, "enrollment_count": 210, "start_date": "2004-10", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134004" }, { "nct_id": "NCT00004132", "title": "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Oral Complications", "Radiation Toxicity" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004132" }, { "nct_id": "NCT03272633", "title": "Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia in Remission", "Hematopoietic Cell Transplantation Recipient", "JAK2 Gene Mutation", "Loss of Chromosome 17p", "Mantle Cell Lymphoma", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Non-Hodgkin Lymphoma", "Plasma Cell Myeloma", "RAS Family Gene Mutation", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hematologic Malignancy", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome", "TP53 Gene Mutation" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Irradiated Allogeneic Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-10-26", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03272633" }, { "nct_id": "NCT03226704", "title": "Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Lymphoma", "Acute Lymphoblastic Leukemia", "Diffuse Large B Cell Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "3 Years to 65 Years" }, "enrollment_count": 120, "start_date": "2017-08-14", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03226704" }, { "nct_id": "NCT03072771", "title": "Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Autologous stem cell transplant", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral blood draws", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-08-01", "completion_date": "2023-10-30", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03072771" }, { "nct_id": "NCT02756247", "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Buparlisib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-05-09", "completion_date": "2022-10-06", "has_results": false, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756247" }, { "nct_id": "NCT00561418", "title": "Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "Correlative studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2007-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-07-16", "last_synced_at": "2026-10-17T01:25:27.974Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561418" } ] }